Abstract
The metabolic syndrome (MetS) is a cluster of risk factors including obesity, insulin resistance, dyslipidemia, elevated blood pressure and glucose intolerance. The MetS increases the risk for cardiovascular disease (CVD) and type 2 diabetes. Each component of the MetS causes cardiac dysfunction and their combination carries additional risk. The mechanisms underlying cardiac dysfunction in the MetS are complex and might include lipid accumulation, increased fibrosis and stiffness, altered calcium homeostasis, abnormal autophagy, altered substrate utilization, mitochondrial dysfunction and increased oxidative stress. Mitochondrial and extra-mitochondrial sources of reactive oxygen species (ROS) and reduced antioxidant defense mechanisms characterize the myocardium of humans and animals with the MetS. The mechanisms for increased cardiac oxidative stress in the MetS are not fully understood but include increased fatty acid oxidation, mitochondrial dysfunction and enhanced NADPH oxidase activity. Therapies aimed to reduce oxidative stress and enhance antioxidant defense have been employed to reduce cardiac dysfunction in the MetS in animals. In contrast, large scale clinical trials using antioxidants therapies for the treatment of CVD have been disappointing because of the lack of efficacy and undesired side effects. The focus of this review is to summarize the current knowledge about the mechanisms underlying cardiac dysfunction in the MetS with a special interest in the role of oxidative stress. Finally, we will update the reader on the results obtained with natural antioxidant and mitochondria-targeted antioxidant therapies for the treatment of CVD in the MetS.
Keywords: Cardiac dysfunction, mitochondrial dysfunction, reactive oxygen species, antioxidants, oxidative stress, substrate utilization, metabolic syndrome, insulin resistance.
Current Pharmaceutical Design
Title:Cardiac Dysfunction and Oxidative Stress in the Metabolic Syndrome: an Update on Antioxidant Therapies
Volume: 19 Issue: 27
Author(s): Olesya Ilkun and Sihem Boudina
Affiliation:
Keywords: Cardiac dysfunction, mitochondrial dysfunction, reactive oxygen species, antioxidants, oxidative stress, substrate utilization, metabolic syndrome, insulin resistance.
Abstract: The metabolic syndrome (MetS) is a cluster of risk factors including obesity, insulin resistance, dyslipidemia, elevated blood pressure and glucose intolerance. The MetS increases the risk for cardiovascular disease (CVD) and type 2 diabetes. Each component of the MetS causes cardiac dysfunction and their combination carries additional risk. The mechanisms underlying cardiac dysfunction in the MetS are complex and might include lipid accumulation, increased fibrosis and stiffness, altered calcium homeostasis, abnormal autophagy, altered substrate utilization, mitochondrial dysfunction and increased oxidative stress. Mitochondrial and extra-mitochondrial sources of reactive oxygen species (ROS) and reduced antioxidant defense mechanisms characterize the myocardium of humans and animals with the MetS. The mechanisms for increased cardiac oxidative stress in the MetS are not fully understood but include increased fatty acid oxidation, mitochondrial dysfunction and enhanced NADPH oxidase activity. Therapies aimed to reduce oxidative stress and enhance antioxidant defense have been employed to reduce cardiac dysfunction in the MetS in animals. In contrast, large scale clinical trials using antioxidants therapies for the treatment of CVD have been disappointing because of the lack of efficacy and undesired side effects. The focus of this review is to summarize the current knowledge about the mechanisms underlying cardiac dysfunction in the MetS with a special interest in the role of oxidative stress. Finally, we will update the reader on the results obtained with natural antioxidant and mitochondria-targeted antioxidant therapies for the treatment of CVD in the MetS.
Export Options
About this article
Cite this article as:
Ilkun Olesya and Boudina Sihem, Cardiac Dysfunction and Oxidative Stress in the Metabolic Syndrome: an Update on Antioxidant Therapies, Current Pharmaceutical Design 2013; 19 (27) . https://dx.doi.org/10.2174/1381612811319270003
DOI https://dx.doi.org/10.2174/1381612811319270003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Cellular Pharmacokinetics of HIV Protease Inhibitors: Current Knowledge and Future Perspectives
Current Drug Metabolism Follicular Immunology Environment and the Influence on In Vitro Fertilization Outcome
Current Women`s Health Reviews Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Metallocarboxypeptidases: Emerging Drug Targets in Biomedicine
Current Pharmaceutical Design Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Current Neuropharmacology Anti-Diabetic
Current Bioactive Compounds Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery An Overview of the Current and Novel Drugs for Alzheimers Disease with Particular Reference to Anti-Cholinesterase Compounds
Current Pharmaceutical Design Assessment of Antihyperglycemic Effect and Acute Toxicity of the Aqueous <i>Scorzonera undulata</i> Extract in Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Early Development of Therapeutic Biologics - Pharmacokinetics
Current Drug Metabolism Determination of Chemical Composition and α-amylase Inhibitory Effect of New Propolis Extracts
Combinatorial Chemistry & High Throughput Screening The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Educational Strategies of Diabetes Group Medical Visits: A Review
Current Diabetes Reviews Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design Microfluidic Devices for Cell, Tissue and Embryo Culture
Recent Patents on Regenerative Medicine Novel Approach to Cardiovascular Diseases: A Promising Probability of (Pro)Renin Receptor [(P)RR]
Current Pharmaceutical Design Reversal of Diabetes and Metabolic Disorders After Bariatric Surgery
Current Nutrition & Food Science